PAUL V MAIER
CIK 1182615 · Chief Financial Officer · last filed 2026-01-14
PAUL V MAIER is a Chief Financial Officer who has filed 129 SEC Form 4 insider transactions across 8 companies since 2008. The most recent filing, for ETON, was dated Jan 14, 2026. Across all open-market trades the lifetime net is +$33.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.89M
8
129
$33.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ETON | Director | 59,745 | $31.59 | $1.89M | $30.0K | 9 | 2026-01-14 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | Director | 85,000 | $28.00 | $2.38M | $0 | 3 | 2024-03-07 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | — | — | — | $0 | 5 | 2020-01-17 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Director | 23,063 | — | — | -$30.3K | 12 | 2018-04-04 |
| SEELOS THERAPEUTICS, INC. (APRI) Delisted | Director | 13,854 | — | — | $0 | 11 | 2018-01-08 |
| SEQUENOM INC (SQNM) Delisted | Chief Financial Officer | 76,927 | — | — | $28.6K | 18 | 2014-02-12 |
| PURE BIOSCIENCE, INC. (PURE) Delisted | Director | 69,110 | — | — | $0 | 2 | 2012-08-02 |
| Talon Therapeutics, Inc. (HNAB) Delisted | Director | 7,000 | — | — | $5.2K | 4 | 2009-02-26 |
Recent Filings
129 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-14 | ETON | Grant (A) | — | $0 | EDGAR |
| 2025-06-20 | — | Grant (A) | — | $0 | |
| 2025-01-06 | ETON | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | — | Grant (A) | — | $0 | |
| 2024-03-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-02-15 | ETON | Grant (A) | — | $0 | EDGAR |
| 2023-06-16 | — | Grant (A) | — | $0 | |
| 2023-06-09 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | +85,000 | $0 | EDGAR |
| 2023-03-03 | ETON | Grant (A) | — | $0 | EDGAR |
| 2023-01-31 | Ambrx Biopharma, Inc. (AMAM) Delisted | Mixed | — | $0 | EDGAR |